ArticleFrontiers in oncology2026
Inflammatory myofibroblastic tumor of the larynx: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal neoplasm characterized by myofibroblastic spindle cells and inflammatory infiltrates. Case summary: We report the case of a 49-year-old female presenting with progressive hoarseness and a right vocal fold mass. Microlaryngoscopy with partial resection was performed without preoperative imaging. Histopathological, immunohistochemical, and molecular analyses were conducted. Histopathological and molecular analyses showed a myofibroblastic spindle cell proliferation with a TIMP3::ALK gene fusion, confirming the diagnosis of IMT. Postoperative recovery was uneventful, and follow-up examinations demonstrated complete remission. Conclusion: Laryngeal inflammatory myofibroblastic tumor (IMT) is a very rare condition, particularly in adults. Complete surgical excision can lead to full remission, but regular follow-up is important due to the risk of recurrence. Immunohistochemical and molecular analyses, especially ALK testing, are essential for accurate diagnosis and evaluation regarding targeted therapy. Further studies are needed to establish clear recommendations for follow-up and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.